- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 317/50 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
Patent holdings for IPC class C07D 317/50
Total number of patents in this class: 79
10-year publication summary
|
3
|
2
|
3
|
6
|
5
|
1
|
7
|
13
|
6
|
6
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10856 |
3 |
| Merck Patent GmbH | 5828 |
3 |
| Givaudan SA | 1860 |
3 |
| National University Corporation Okayama University | 469 |
3 |
| Tasly Pharmaceutical Group Co., Ltd. | 119 |
3 |
| Terran Biosciences, Inc. | 94 |
3 |
| Bristol-myers Squibb Company | 4875 |
2 |
| CHDI Foundation, Inc. | 108 |
2 |
| Godavari Biorefineries Limited | 39 |
2 |
| Anthea Aromatics Private Limited | 11 |
2 |
| Mind Medicine Inc. | 100 |
2 |
| Lhotse bio, Inc. | 11 |
2 |
| Sumitomo Chemical Company, Limited | 9046 |
1 |
| The Board of Trustees of the Leland Stanford Junior University | 6403 |
1 |
| DSM IP Assets B.V. | 5595 |
1 |
| Board of Regents, The University of Texas System | 5782 |
1 |
| JSR Corporation | 2512 |
1 |
| Korea Institute of Science and Technology | 2115 |
1 |
| Vertex Pharmaceuticals Incorporated | 1599 |
1 |
| University of Florida Research Foundation, Inc. | 4016 |
1 |
| Other owners | 41 |